189 related articles for article (PubMed ID: 38211604)
1. Efficacy and safety of linaclotide in treating functional constipation in paediatric patients: a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.
Di Lorenzo C; Khlevner J; Rodriguez-Araujo G; Xie W; Huh SY; Ando M; Hyams JS; Nurko S; Benninga MA; Simon M; Hewson ME; Saps M
Lancet Gastroenterol Hepatol; 2024 Mar; 9(3):238-250. PubMed ID: 38211604
[TBL] [Abstract][Full Text] [Related]
2. Low-Dose Linaclotide (72 μg) for Chronic Idiopathic Constipation: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial.
Schoenfeld P; Lacy BE; Chey WD; Lembo AJ; Kurtz CB; Reasner DS; Bochenek W; Tripp K; Currie MG; Fox SM; Blakesley RE; OʼDea CR; Omniewski ND; Hall ML
Am J Gastroenterol; 2018 Jan; 113(1):105-114. PubMed ID: 29091082
[TBL] [Abstract][Full Text] [Related]
3. Naldemedine versus placebo for opioid-induced constipation (COMPOSE-1 and COMPOSE-2): two multicentre, phase 3, double-blind, randomised, parallel-group trials.
Hale M; Wild J; Reddy J; Yamada T; Arjona Ferreira JC
Lancet Gastroenterol Hepatol; 2017 Aug; 2(8):555-564. PubMed ID: 28576452
[TBL] [Abstract][Full Text] [Related]
4. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of linaclotide for opioid-induced constipation in patients with chronic noncancer pain syndromes from a phase 2 randomized study.
Brenner DM; Argoff CE; Fox SM; Bochenek W; D'Astoli P; Blakesley RE; Reasner DS; O'Dea CR; Cash BD
Pain; 2020 May; 161(5):1027-1036. PubMed ID: 32310620
[TBL] [Abstract][Full Text] [Related]
6. Linaclotide in irritable bowel syndrome with constipation: A Phase 3 randomized trial in China and other regions.
Yang Y; Fang J; Guo X; Dai N; Shen X; Yang Y; Sun J; Bhandari BR; Reasner DS; Cronin JA; Currie MG; Johnston JM; Zeng P; Montreewasuwat N; Chen GZ; Lim S
J Gastroenterol Hepatol; 2018 May; 33(5):980-989. PubMed ID: 29319191
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of linaclotide for patients with chronic constipation.
Lembo AJ; Kurtz CB; Macdougall JE; Lavins BJ; Currie MG; Fitch DA; Jeglinski BI; Johnston JM
Gastroenterology; 2010 Mar; 138(3):886-95.e1. PubMed ID: 20045700
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
9. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
Rao S; Lembo AJ; Shiff SJ; Lavins BJ; Currie MG; Jia XD; Shi K; MacDougall JE; Shao JZ; Eng P; Fox SM; Schneier HA; Kurtz CB; Johnston JM
Am J Gastroenterol; 2012 Nov; 107(11):1714-24; quiz p.1725. PubMed ID: 22986440
[TBL] [Abstract][Full Text] [Related]
10. Dose-finding study of linaclotide in Japanese patients with chronic constipation: A phase II randomized, double-blind, and placebo-controlled study.
Fukudo S; Miwa H; Nakajima A; Kinoshita Y; Kosako M; Nakagawa A; Akiho H; Kuroishi K; Johnston JM; Currie M; Ohkusa T
Neurogastroenterol Motil; 2018 Dec; 30(12):e13442. PubMed ID: 30084233
[TBL] [Abstract][Full Text] [Related]
11. Linaclotide in Chronic Idiopathic Constipation Patients with Moderate to Severe Abdominal Bloating: A Randomized, Controlled Trial.
Lacy BE; Schey R; Shiff SJ; Lavins BJ; Fox SM; Jia XD; Blakesley RE; Hao X; Cronin JA; Currie MG; Kurtz CB; Johnston JM; Lembo AJ
PLoS One; 2015; 10(7):e0134349. PubMed ID: 26222318
[TBL] [Abstract][Full Text] [Related]
12. High-dose linaclotide is effective and safe in patients with chronic constipation: A phase III randomized, double-blind, placebo-controlled study with a long-term open-label extension study in Japan.
Fukudo S; Miwa H; Nakajima A; Kinoshita Y; Kosako M; Hayashi K; Akiho H; Kuroishi K; Johnston JM; Currie M; Ohkusa T
Neurogastroenterol Motil; 2019 Jan; 31(1):e13487. PubMed ID: 30353619
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of the sodium-glucose cotransporter 1 inhibitor mizagliflozin for functional constipation: a randomised, placebo-controlled, double-blind phase 2 trial.
Fukudo S; Endo Y; Hongo M; Nakajima A; Abe T; Kobayashi H; Nakata T; Nakajima T; Sameshima K; Kaku K;
Lancet Gastroenterol Hepatol; 2018 Sep; 3(9):603-613. PubMed ID: 30056028
[TBL] [Abstract][Full Text] [Related]
14. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
Fukudo S; Nakajima A; Fujiyama Y; Kosako M; Nakagawa A; Akiho H; Nakashima Y; Johnston JM; Miwa H
Neurogastroenterol Motil; 2018 May; 30(5):e13275. PubMed ID: 29278278
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of the muscarinic receptor agonist KarXT (xanomeline-trospium) in schizophrenia (EMERGENT-2) in the USA: results from a randomised, double-blind, placebo-controlled, flexible-dose phase 3 trial.
Kaul I; Sawchak S; Correll CU; Kakar R; Breier A; Zhu H; Miller AC; Paul SM; Brannan SK
Lancet; 2024 Jan; 403(10422):160-170. PubMed ID: 38104575
[TBL] [Abstract][Full Text] [Related]
16. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study.
Bussel JB; de Miguel PG; Despotovic JM; Grainger JD; Sevilla J; Blanchette VS; Krishnamurti L; Connor P; David M; Boayue KB; Matthews DC; Lambert MP; Marcello LM; Iyengar M; Chan GW; Chagin KD; Theodore D; Bailey CK; Bakshi KK
Lancet Haematol; 2015 Aug; 2(8):e315-25. PubMed ID: 26688484
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial.
Grainger JD; Locatelli F; Chotsampancharoen T; Donyush E; Pongtanakul B; Komvilaisak P; Sosothikul D; Drelichman G; Sirachainan N; Holzhauer S; Lebedev V; Lemons R; Pospisilova D; Ramenghi U; Bussel JB; Bakshi KK; Iyengar M; Chan GW; Chagin KD; Theodore D; Marcello LM; Bailey CK
Lancet; 2015 Oct; 386(10004):1649-58. PubMed ID: 26231455
[TBL] [Abstract][Full Text] [Related]
18. Randomized controlled trial of linaclotide in children aged 6-17 years with functional constipation.
Di Lorenzo C; Nurko S; Hyams JS; Rodriguez-Araujo G; Almansa C; Shakhnovich V; Saps M; Simon M
J Pediatr Gastroenterol Nutr; 2024 May; 78(5):1059-1068. PubMed ID: 38533633
[TBL] [Abstract][Full Text] [Related]
19. Safety and efficacy of linaclotide in children aged 7-17 years with irritable bowel syndrome with constipation.
Di Lorenzo C; Nurko S; Hyams JS; Rodriguez-Araujo G; Shakhnovich V; Saps M; Simon M
J Pediatr Gastroenterol Nutr; 2024 Mar; 78(3):539-547. PubMed ID: 38504394
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation: Chinese sub-cohort analysis of a phase III, randomized, double-blind, placebo-controlled trial.
Peng LH; Fang JY; Dai N; Shen XZ; Yang YL; Sun J; Yang YS
J Dig Dis; 2022 Feb; 23(2):99-110. PubMed ID: 35019221
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
